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Abstract: 
The present study examined the validity of psychometrically assessed positive and negative 
schizotypy in a study of 214 Spanish young adults using interview and questionnaire measures of 
impairment and psychopathology. Schizotypy provides a useful construct for understanding the 
etiology and development of schizophrenia and related disorders. Recent interview, laboratory, 
and experience sampling studies have supported the validity of psychometrically assessed 
positive and negative symptom dimensions. The present study expands on previous findings by 
examining the validity of these dimensions in a Spanish sample and employing a widely used 
interview measure of the schizophrenia prodrome. As hypothesized, the positive schizotypy 
dimension predicted CAARMS ultra high-risk or psychosis threshold status, and both 
dimensions uniquely predicted the presence of schizophrenia-spectrum personality disorders. 
Furthermore, positive schizotypy was associated with psychotic-like, paranoid, schizotypal, and 
mood symptoms, whereas negative schizotypy was associated with interview ratings of negative 
and schizoid symptoms. The schizotypy dimensions were also distinguished by their associations 
with self and other schemas. Positive schizotypy was associated with increased negative self and 
other schemas, whereas negative schizotypy was associated with decreased positive self and 
other schemas. The findings provide further construct validation of positive and negative 
schizotypy and support these dimensions as universal constructs. 
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1. Introduction 
Recent conceptualizations indicate that the underlying vulnerability for schizophrenia is 
expressed across a dynamic continuum of symptoms and impairment referred to as schizotypy 
(e.g., Claridge, 1997, Lenzenweger, 2010 and Kwapil and Barrantes-Vidal, 2012). Rather than 
viewing schizotypy and schizophrenia as qualitatively distinct, schizophrenia, related spectrum 
disorders, and the prodrome represent the most extreme manifestations of the schizotypy 
continuum. The reliable assessment of schizotypy should enhance identification of relevant 
etiological factors and endophenotypes, facilitate understanding of developmental trajectories 
(including risk and protective factors), and is essential for developing prophylactic interventions. 
 
Schizotypy, and by extension schizophrenia, is conceptualized as multidimensional, with 
positive and negative schizotypy the most consistently replicated factors. Positive schizotypy is 
characterized by odd beliefs, unusual perceptual experiences, negative affect, and affective 
dysregulation, whereas negative schizotypy involves avolition, asociality, diminished positive 
affect, and anergia (e.g., Vollema and van den Bosch, 1995). The conceptualization and 
measurement of schizotypy and schizophrenia as multidimensional are essential for advancing 
our understanding of these constructs. Studies that treat them as homogenous often produce 
mixed, equivocal, or non-replicable results because these dimensions are associated with distinct 
etiologies, presentations, and treatment responses. 
 
The psychometric assessment of schizotypy offers unique benefits such as being relatively 
inexpensive, noninvasive, and useful for screening large samples of the general population, as 
well as clinical samples (Kwapil et al., 2008). The Wisconsin Schizotypy Scales (WSS), 
including the Perceptual Aberration (Chapman et al., 1978), Magical Ideation (Eckblad and 
Chapman, 1983), Physical Anhedonia (Chapman et al., 1976), and Revised Social Anhedonia 
(Eckblad et al., 1982) Scales, are widely used, exhibit sound psychometric properties, and are 
associated cross-sectionally with schizophrenic-like symptoms and impairment, and 
longitudinally with development of schizophrenia-spectrum disorders (Chapman et al., 1994, 
Kwapil, 1998 and Gooding et al., 2005). 
 
Kwapil et al. (2008) conducted a series of confirmatory factor analyses to investigate the 
dimensional structure of the WSS and found support for a hypothesized two-factor model with 
positive and negative schizotypy dimensions that was invariant across gender and ethnicity. 
Preliminary construct validity for these dimensions was demonstrated through differential 
patterns of associations with psychopathology, personality, and impairment. As hypothesized, 
positive but not negative schizotypy was associated with psychotic-like experiences, substance 
abuse, mood disorders, and mental health treatment, whereas negative schizotypy was uniquely 
related to interview-based ratings of negative and schizoid symptoms. Both dimensions were 
associated with schizotypal and paranoid symptoms, and impairment in functioning. However, 
the study did not include criteria assessing prodromal symptoms or classifications. 
 
Schizotypy and schizophrenia are presumed to be universal constructs; therefore Kwapil et al. 
(2012c) examined the factor invariance of the WSS in Spanish and American samples. As 
hypothesized, positive and negative schizotypy factors provided the best fit and this structure 
was invariant across the samples, consistent with findings in a Spanish sample by Fonseca-
Pedrero et al. (2010), and supporting previous evidence of the cross-cultural consistency of 
schizotypy dimensions (Chen et al., 1997 and Reynolds et al., 2000). However, studies assessing 
the cross-cultural construct validity of these dimensions are needed. 
 
1.1. Goals and hypotheses of the present study 
The primary goal of the present study was to examine the validity of psychometrically assessed 
positive and negative schizotypy in a non-clinically ascertained sample of young adults. The 
study sought to replicate findings that positive and negative schizotypy were associated with 
differential patterns of symptoms and impairment. It also expanded upon earlier studies by 
employing a measure of the schizophrenia prodrome, assessing a broader range of personality 
disorders, increasing assessment of affective symptoms, and including measures of self and other 
schemas and self-esteem. Both cognitive models of psychosis (e.g., Garety et al., 2007) and 
empirical evidence (Fowler et al., 2012 and Stowkowy and Addington, 2012) implicate 
maladaptive schemas in the development and maintenance of psychotic symptoms. Furthermore, 
the study sought to examine the cross-cultural validity of the schizotypy dimensions by assessing 
a Spanish sample. 
 
It was hypothesized that both schizotypy dimensions would be associated with schizotypal, 
paranoid, and avoidant personality traits, suspiciousness, and impaired functioning. Positive 
schizotypy was expected to be associated with psychotic-like symptoms and measures assessing 
negative affect, including anxiety, depression, borderline personality, low self-esteem, and 
negative schemas. In contrast, it was predicted that negative schizotypy would be associated with 




The present study is part of an ongoing longitudinal project examining risk for psychosis. The 
participants were drawn from a screening sample of 589 undergraduates at the Universitat 
Autónoma de Barcelona. Usable screening data was obtained from 547 participants (42 were 
excluded due to invalid protocols). The mean age was 20.6 years (SD = 4.1) and 83% were 
female. A subset of 339 participants was invited to take part in an assessment including self-
report, interview, and laboratory measures with the goal of assessing 200 individuals. We invited 
all 189 who had standard scores based upon sample norms of at least 1.0 on the positive or 
negative schizotypy dimension, the suspiciousness subscale of the Schizotypal Personality 
Questionnaire (SPQ; Raine, 1991), or the positive symptom subscale of the Community 
Assessment of Psychic Experiences (CAPE; Stefanis et al., 2002), and 150 randomly selected 
participants who had standard scores < 1.0 on each of these measures. The goal of the 
enrichment procedure was to ensure adequate representation of schizotypy in the sample. A total 
of 214 participants (78% females) with a mean age of 21.4 years (SD = 2.4) completed the 
assessment. The sample included 123 participants with elevated schizotypy scores and 91 with 
standard scores below 1.0. Note that the four scales contributed approximately equal numbers of 
participants with elevated z-scores (ranging from 50 with elevated scores on WSS positive 
schizotypy to 57 with elevations on the SPQ suspiciousness). 
 
2.2. Materials and procedure 
At the initial assessment, students completed a battery of self-report measures. At the second 
assessment, participants were administered diagnostic interviews and questionnaires (along with 
measures not used in this study). The interviews were conducted by psychologists and advanced 
graduate students in clinical psychology. All interviewers were extensively trained and were 
unaware of participants' scores on the screening questionnaires. Individuals were paid for their 
participation. Ethical approval for the study was granted by the University Ethics Committee and 
participants provided informed consent at both assessments. 
 
2.2.1. Time 1 measures 
Participants were administered the WSS intermixed with an infrequency scale (Chapman and 
Chapman, 1983). The Perceptual Aberration Scale assesses psychotic-like bodily distortions and 
perceptual experiences, the Magical Ideation Scale taps belief in invalid causation, the Revised 
Social Anhedonia Scale measures schizoid asociality, and the Physical Anhedonia Scale assesses 
deficits in sensory and esthetic pleasure. The Spanish adaptation of the WSS was used (Ros-
Morente et al., 2010), which has shown good reliability in college samples and external validity 
(e.g., Barrantes-Vidal et al., 2003). Participants were assigned positive and negative schizotypy 
factor scores based upon norms from 6137 American young adults (Kwapil et al., 2008). Note 
that Kwapil et al. (2012c) demonstrated that the positive and negative schizotypy factor structure 
underlying the scales was invariant in Spanish and American samples. Furthermore, the norm-
based factor scores correlated .99 with factor scores generated from a principal components 
analysis with the Spanish sample of 547. 
 
Participants completed the CAPE, which measures positive, negative, and depressive symptoms, 
as well as the suspiciousness subscale of the SPQ. The depression and anxiety subscales of the 
Symptom Checklist-90-Revised (SCL-90-R; Derogatis, 1977) were used to assess emotional 
state. Beliefs about the self and others were evaluated with the Brief Core Schema Scales (BCSS; 
Fowler et al., 2006), which yields subscale scores for negative-self, positive-self, negative-
others, and positive-others. Participants took 1.5 to 2 h to complete the time 1 assessment. 
 
2.2.2. Time 2 measures 
The Comprehensive Assessment of At-Risk Mental States (CAARMS; Yung et al., 2005) is a 
structured interview that assesses the psychosis prodrome. Severity scores for seven CAARMS 
subscales were used. The CAARMS was also used to assess criteria for ultra high-risk status. 
The Structured Clinical Interview for DSM-IV Axis II Disorders (First et al., 1997) was used to 
assess schizophrenia-spectrum personality disorders and provide dimensional ratings. Depression 
was assessed with the Calgary Depression Scale (Addington et al., 1992) and the Beck 
Depression Inventory-II (Beck et al., 1996) and self-esteem with the Rosenberg Self-Esteem 
Scale (Rosenberg, 1965). Functioning was rated using the Social and Occupational Functioning 
Assessment Scale (Goldman et al., 1992) and the Global Assessment of Functioning (American 
Psychiatric Association, 2000). Participants took 1.5 to 3 h to complete the time 2 assessment. 
 
3. Results 
3.1. Descriptive statistics 
The mean for positive schizotypy was − .31 (SD = .89, range = − 1.56 to 3.23) and for negative 
schizotypy was .01 (SD = 1.05, range = − 1.57 to 4.27). Both dimensions were unimodal and 
positively skewed. The schizotypy dimensions were not significantly correlated (r = .11). 




Table 1. Descriptive statistics for quantitative dependent measures of symptoms, impairment, 
and personality. 
Measure Mean SD Range Alphaa 
CAPE positive symptoms 8.39 4.84 0–23 .76 
CAPE negative symptoms 10.59 5.80 0–35 .83 
SPQ suspiciousness 2.97 2.05 0–8 .71 
CAARMS positive symptoms 1.21 2.69 0–24 – 
CAARMS negative symptoms 1.51 2.39 0–11 – 
CAARMS cognitive symptoms 0.91 1.50 0–8 – 
CAARMS emotional disturbance 0.94 1.91 0–11 – 
CAARMS behavioral symptoms 1.36 2.05 0–9 – 
CAARMS motor symptoms 1.00 1.76 0–14 – 
CAARMS general psychopathology 3.69 3.85 0–21 – 
Schizotypal personality rating 1.00 1.93 0–13 – 
Schizoid personality rating 0.90 1.54 0–8 – 
Paranoid personality rating 1.53 2.08 0–12 – 
Avoidant personality rating 2.11 2.82 0–14 – 
Borderline personality rating 1.43 2.27 0–12 – 
Social and occupational functioning 86.5 8.4 40–100 – 
Global assessment of functioning 85.5 10.3 51–100 – 
Rosenberg total 23.1 4.6 3–30 .87 
BCSS negative self 2.68 3.00 0–16 .65 
BCSS negative others 3.20 3.53 0–17 .77 
BCSS positive self 12.42 4.73 2–24 .81 
Measure Mean SD Range Alphaa 
BCSS positive others 10.29 4.85 0–21 .84 
SCL-90-R anxiety 6.99 5.65 0–29 .81 
SCL-90-R depression 12.33 8.23 0–43 .86 
Calgary depression scale 1.21 2.07 0–13 – 
Beck depression inventory 5.33 5.33 0–29 .81 
CAPE depression 6.08 2.93 1–18 .75 
 
a Coefficient alpha reported for questionnaire measures only. 
3.2. Validity of the schizotypy dimensions 
In order to assess the validity of the schizotypy dimensions, a series of hierarchical linear 
regressions were computed that examined the variance accounted for by positive and negative 
schizotypy and their interaction in measures of psychopathology, personality, and functioning. 
Positive and negative schizotypy dimension scores were entered simultaneously in the regression 
at the first step to examine their unique contribution. The interaction term was entered at the 
second step to assess its effect over-and-above the main effects. The standardized regression 
coefficient (β), semi-partial r2, and effect size f2 were reported for each predictor in the linear 
regressions. According to Cohen (1992), f2 values above .15 are medium and above .35 are large 
effect sizes (however, note that designs that employ oversampling can lead to inflated estimates 
of effect sizes). Given that many of the continuous dependent variables were skewed (especially 
measures of psychopathology), maximum likelihood estimation and bootstrap procedures (with 
2000 samples) were employed. Given the large number of linear regressions, alpha level was set 
at .01 to minimize Type I error and reduce the likelihood of reporting statistically significant but 
inconsequential findings. 
 
Table 2 presents the results of analyses examining the prediction of schizophrenia-spectrum, 
prodromal, and personality disorder symptoms. As expected, negative schizotypy was 
significantly associated with ratings of negative and schizoid symptoms, and with affective 
flattening. It was also associated with schizotypal and avoidant personality ratings and 
suspiciousness. Positive schizotypy was significantly associated with all of the outcome 
measures except for schizoid and motoric symptoms. 
 
Table 2. Linear regressions of questionnaire and interview measures of schizophrenia-spectrum 
and prodromal symptoms (n = 214). 
 Step 1 (df = 211) 
 








Criterion β Δr2 f2 β Δr2 f2 β Δr2 f2 
CAPE positive symptoms .708⁎ .496 .99 .001 .000 .00 -.016 .000 .00 
CAPE negative symptoms .382⁎ .144 .22 .402⁎ .160 .24 .089 .008 .01 
SPQ suspiciousness .554⁎ .304 .50 .237⁎ .056 .09 .021 .000 .00 
CAARMS positive symptoms .300⁎ .089 .10 .166 .027 .03 .089 .008 .01 
CAARMS negative symptoms .330⁎ .108 .13 .195⁎ .037 .05 .104 .011 .01 
CAARMS cognitive symptoms .181⁎ .032 .03 .136 .018 .02 -.087 .008 .01 
CAARMS emotional disturbance .206⁎ .042 .05 .347⁎ .119 .15 .065 .004 .01 
CAARMS behavioral symptoms .315⁎ .098 .11 .149 .022 .03 .066 .004 .00 
CAARMS motor symptoms .142 .020 .02 .154 .024 .03 -.057 .003 .00 
CAARMS general psychopathology .248⁎ .061 .07 .189⁎ .035 .04 .091 .008 .01 
Schizotypal personality rating .309⁎ .094 .12 .285⁎ .080 .10 .102 .010 .01 
Schizoid personality rating .100 .010 .01 .473⁎ .221 .29 -.081 .006 .01 
Paranoid personality rating .356⁎ .125 .15 .145 .021 .02 .135 .018 .02 
Avoidant personality rating .322⁎ .102 .12 .246⁎ .060 .07 .130 .017 .02 
Borderline personality rating .347⁎ .119 .14 .109 .012 .01 .088 .008 .01 
 ⁎ p < .01; Medium effect sizes in bold, large effect sizes in bold and italics. 
 
The finding that positive schizotypy was associated with CAPE and CAARMS ratings of 
negative symptoms is counterintuitive. However, both of these purported measures of negative 
symptoms appear to be saturated with depression and positive symptoms. The CAPE negative 
symptom scale correlated highly with CAPE depression (r = .57), SCL-90 depression (r = .60), 
and CAPE positive symptoms (r = .41), but only modestly with schizoid personality symptoms (r 
= .32). Likewise, CAARMS negative symptom ratings correlated higher with CAARMS positive 
symptoms (r = .51) and depression (r = .46), than with schizoid symptoms (r = .29). As an 
exploratory analysis, we recomputed the regression predicting CAPE negative symptoms after 
partialling out CAPE positive and depression symptoms. The association with positive 
schizotypy was no longer significant, but the association with negative schizotypy remained 
significant (confirming concerns about the CAPE negative symptom scale). The schizoid 
dimensional score, which was associated with negative but not positive schizotypy, appears to 
provide a better measure of negative symptoms than the CAPE or CAARMS. 
 
Table 3 presents the results of analyses assessing functioning, self, and mood. Both schizotypy 
dimensions were associated with impaired functioning. As hypothesized, positive schizotypy was 
associated with measures of anxiety and depression. In contrast, negative schizotypy was 
generally unassociated with anxiety and depression. Likewise, positive schizotypy was 
associated with low self-esteem and negative schemas of self and others; whereas, negative 
schizotypy was associated with diminished positive schemas. 
Table 3. Linear regressions of interview measures of functioning, self, and mood (n = 214). 
 Step 1 (df = 211) 
 








Criterion β Δr2 f2 β Δr2 f2 β Δr2 f2 
Social and occupational functioning − .247⁎ .060 .07 − .271⁎ .072 .09 − .072 .005 .01 
Global assessment of functioning − .271⁎ .072 .09 − .259⁎ .066 .08 − .035 .001 .00 
Rosenberg total − .377⁎ .141 .17 − .191⁎ .036 .04 − .072 .005 .01 
SCL-90-R anxiety .507⁎ .254 .35 .105 .011 .02 .024 .001 .00 
SCL-90-R depression .447⁎ .198 .25 .183⁎ .033 .04 .175 .030 .04 
Calgary depression scale .201⁎ .043 .04 .088 .008 .01 .099 .010 .01 
Beck depression inventory .344⁎ .117 .14 .173 .029 .03 .111 .012 .01 
CAPE depression .460⁎ .210 .28 .163 .026 .03 .189⁎ .035 .05 
BCSS negative self .226⁎ .050 .05 .174 .030 .03 .154 .023 .05 
BCSS negative others .416⁎ .171 .21 .053 .003 .00 .033 .001 .00 
BCSS positive self − .058 .003 .00 − .357⁎ .126 .15 − .027 .001 .00 
BCSS positive others − .140 .019 .02 − .405⁎ .162 .20 .008 .000 .00 
⁎ p < .01; Medium effect sizes in bold, large effect sizes in bold and italics. 
 
In order to assess the prediction of diagnostic criteria by the schizotypy dimensions, binary 
logistic regressions were computed. Schizophrenia-spectrum personality disorders were reported 
by 10 participants: 5 with Avoidant, 2 with Schizotypal, 4 with Paranoid, and 3 with Borderline 
Personality Disorders (3 qualified for more than one disorder). Both positive (OR = 1.96, 95%CI 
= 1.08–3.58) and negative (OR = 1.89, 95%CI = 1.12–3.27) schizotypy significantly predicted 
schizophrenia-spectrum personality disorders. The interaction term was not significant (OR = 
1.00, 95%CI = 0.60–1.65). Note that when we examined the association of the schizotypy 
dimensions with individual personality disorders, positive schizotypy significantly uniquely 
predicted schizotypal (OR = 3.43, 95%CI = 1.03–11.50) and paranoid (OR = 2.68, 95%CI = 
1.14–6.36) personality disorders. Negative schizotypy predicted avoidant personality disorder 
(OR = 2.25, 95%CI = 1.13–4.51). Thus, the schizotypy dimensions were associated with 
quantitative and categorical assessments of personality pathology. 
 
Criteria for CAARMS ultra high-risk status or psychosis threshold were met by 9 of the 
participants: 2 met vulnerability criteria, 8 met attenuated psychosis criteria, and 1 met psychosis 
threshold criteria (2 met both vulnerability and attenuated criteria). Positive schizotypy (OR = 
2.16, 95%CI = 1.17–4.00) significantly predicted CAARMS prodromal group membership. 
Neither negative schizotypy (OR = 1.47, 95%CI = 0.82–2.61) nor the schizotypy interaction (OR 
= 0.76, 95%CI = 0.44–1.31) was significant. 
 
4. Discussion 
Current approaches to understanding risk for psychopathology conceptualize schizotypy as the 
expression of underlying developmental vulnerability for schizophrenia. Psychometrically 
assessed positive and negative schizotypy provide a useful point of entry for understanding 
developmental trajectories, potential endophenotypes, and risk and protective factors. Further, 
schizotypy provides a unique framework for identifying points of intervention for preventative 
treatment. Numerous studies support the multidimensionality of schizophrenia, with positive, 
negative, and disorganized factors as the leading candidates. Consistent with the model that 
schizophrenia represents the most extreme manifestation of the schizotypy continuum, 
schizotypy and schizophrenia exhibit a similar factor structure. However, researchers frequently 
treat schizophrenia and schizotypy as homogenous constructs, thus ignoring within-group 
heterogeneity. This practice runs the risk of obscuring true endophenotypes and necessarily falls 
short in explaining the heterogeneity seen in the etiology, symptom presentation, and treatment 
responses in schizotypy and schizophrenia. This study provided further evidence for the validity 
of positive and negative schizotypy as distinct dimensions. 
 
Consistent with previous work (e.g., Kwapil et al., 2008), the negative schizotypy dimension was 
associated with impaired functioning and with interview-based ratings of negative, schizoid, and 
schizotypal symptoms. The present study extended these findings by indicating that negative 
schizotypy was associated with prodromal measures of emotional disturbance (consistent with 
reports of affective flattening in daily life by Kwapil et al., 2012a). Positive schizotypy was 
related to all outcome measures except schizoid and motoric symptoms. This study extended our 
previous findings by examining the association of the schizotypy dimensions with measures of 
the schizophrenia prodrome. It is important to keep in mind that positive and negative schizotypy 
were associated with the hypothesized pattern of symptoms and impairment in a non-clinically 
ascertained sample. As in Kwapil et al. (2008), positive and negative schizotypy were uniquely 
associated with schizophrenia-spectrum symptoms, despite the fact that the participants in the 
study were functioning well enough to enroll in a university. 
 
The finding that the positive and negative schizotypy interaction term generally did not account 
for additional variance is consistent with our previous studies and suggests that the effects of the 
dimensions tend to be additive. This additive effect is supported by Barrantes-Vidal et al.'s 
(2010) findings of marked deviancy for a combined positive and negative schizotypy cluster. 
 
This study was the first to investigate the validity of the positive and negative schizotypy 
dimensions in a non-North American sample using interview measures. Previous studies have 
indicated that the two-factor structure underlying the WSS is invariant across Spanish (Kwapil et 
al., 2012c) and French (Qunbar et al., 2012) samples, and the present findings supported the 
validity of these dimensions in a Spanish sample. The findings provide evidence that positive 
and negative schizotypy are global or cross-cultural constructs—although future studies should 
examine the validity of these dimensions in other cultures and languages. 
 
Consistent with previous findings, positive schizotypy was associated with measures of anxiety 
and depression, and with low self-esteem and negative schemas. In contrast, negative schizotypy 
was associated with diminished positive self and other schemas. This pattern of results highlights 
the differential role of affect, such that positive schizotypy tends to be characterized by affect 
dysregulation and high negative affect, whereas negative schizotypy is associated with 
diminished positive affect (Krabbendam et al., 2002, Lewandowski et al., 2006, Barrantes-Vidal 
et al., 2009 and Armando et al., 2010). This distinction offers insight into the long-term 
trajectories of the dimensions, such as social anxiety for positive and schizoid withdrawal for 
negative schizotypy, and also has the potential to isolate specific mechanisms that can be 
targeted with treatment interventions. 
 
Both positive and negative schizotypy significantly predicted ratings of Avoidant Personality 
Disorder; however, it appears that distinct mechanisms are involved. Specifically, those with 
primarily positive features may be more likely to avoid contact with others due to social anxiety, 
low self-esteem, and social rejection. This is consistent with experience sampling findings that 
positive schizotypy is associated with a desire to be alone when with others because of anxiety 
(Kwapil et al., 2012a). Those with negative schizotypy, on the other hand, likely avoid others 
due to diminished motivation for and pleasure from interacting with others. This is consistent 
with experience sampling findings that negative schizotypy was associated with a desire to be 
alone that was moderated by diminished positive affect, not increased negative affect. 
 
The finding that the positive schizotypy dimension was associated with questionnaire (CAPE) 
and interview (CAARMS) measures of negative symptoms is inconsistent with our previous 
findings and contrary to our hypotheses. Note that Kwapil et al. (2008) reported that positive 
schizotypy was not significantly associated with interview-based ratings on the Negative 
Symptom Manual (Kwapil and Dickerson, 2001) or schizoid symptoms. Furthermore, previous 
studies using the Perceptual Aberration and Magical Ideation Scales (e.g., Kwapil et al., 2002), 
which account for the majority of the variance in the positive schizotypy dimension, found that 
these scales were unassociated with negative or schizoid symptoms. Consistent with previous 
findings, the positive schizotypy dimension was not associated with schizoid symptoms in the 
present study. We suggest that the most likely explanation is that the CAPE and CAARMS 
negative symptom measures do not adequately measure the construct, as evidenced by their high 
correlations with positive symptoms and depression. Despite the fact that depressive symptoms 
are more strongly associated with positive schizotypy than with negative schizotypy, negative 
symptoms and depression share a number of phenomenological similarities. Therefore, it is 
essential that measures of negative symptoms are not confounded by variance associated with 
depression or by positive symptoms. 
 
Negative symptoms of schizotypy and schizophrenia involve anhedonia, withdrawal, affective 
flattening, anergia, avolition, and diminished vitality and cognition. One possible concern about 
our schizotypy dimension is that it is based on measures of anhedonia and, to a lesser extent, 
social withdrawal. As a result, it may not fully capture the construct of negative symptoms. 
However, an increasing number of studies have demonstrated that this dimension is associated 
with interview ratings of negative and schizoid symptoms, but not depression. These findings 
provide striking evidence that trait anhedonia is a significant component of negative symptoms 
of schizotypy and schizophrenia. 
 
The present findings provided further support for the construct validity of the positive and 
negative schizotypy dimensions. However, several other candidate dimensions have been 
proposed and require further study including cognitive and behavioral disorganization (Claridge 
et al., 1996, Reynolds et al., 2000 and Vollema and Hoijtink, 2000), paranoia (Stefanis et al., 
2004), and nonconformity (Claridge et al., 1996). The present findings are limited by being 
cross-sectional. Recent re-evaluation of the Chapmans' ten-year longitudinal study data indicates 
that the positive schizotypy dimension predicts the development of psychotic disorders, 
including non-mood and mood psychoses, in a sample of former college students and that both 
dimensions uniquely predict the development of schizophrenia-spectrum disorders, including 
Cluster A personality disorders (Kwapil et al., 2012b). Both dimensions were also associated 
with a differential pattern of impairment and psychotic-like and schizotypic symptoms, 
consistent with the present findings. We are currently reassessing the present sample to examine 
the predictive validity of the positive and negative symptom dimensions. 
 
Additional research is needed to address the limitations of the present study. Data from 
community samples with a representative distribution in terms of age and gender would enhance 
the generalizability of the current findings, which were based on a relatively high-functioning 
sample with a predominance of female participants and a narrow age range. However, the fact 
that the findings drawn from a college student sample supported the hypotheses and mirror those 
reported in clinical and community populations is especially striking. Future studies should 
continue to examine the cross-cultural validity of these dimensions in other Western and non-
Western cultures and languages to increase our understanding of the universality of these 
dimensions. 
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